Prostate cancer is the most common non-cutaneous malignancy in men and second most common cause of cancer-specific mortality. Determining the type of cancer remains a significant challenge in management. Novel translational research has helped to guide these decisions to maximize oncologic outcomes while minimizing morbidity of over treatment. Integration of tumor biology with clinical practice may lead to a more individualized, patient-specific treatment plan.
Prostate cancer represents a spectrum ranging from low-grade, localized tumors to devastating metastatic disease. Novel treatment options aim to achieve a higher therapeutic index. The risk stratification of clinically localized prostate cancer has served as a guide to counsel patients on treatment option. Prostate cancer detection Due to a shift in disease stage at presentation, the proportion of patients presenting with…
